Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stop dasatinib study in CML-CP patients with sustained complete molecular response
jRCTs071180043Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dasatinib in chronic myelogenous leukemia (CML), sponsored by Bristol Myers Squibb. Primary endpoint: CMR maintenance rate at 1 year after dasatinib discontinuation. Started Aug 2012; status: completed.
02
Drugs
dasatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCTs071180043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180043.